These studies resulted in the identification of molecular targets, whose suppression induces remarkable clinical responses with minimal toxicities, enabling control of disease over months or even years, such as with inhibitors of mutant EGFR and anaplastic lymphoma kinase (ALK) in lung cancers. The gene discussed is ALK; the disease is lung cancer.